| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 367-377 |
| Journal | Alzheimers & Dementia |
| Volume | 6 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2010 |
Cite this
Schneider, L. S., Kennedy, R. E., Cutter, G. R., & Fox, N. C. (2010). Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers & Dementia, 6(5), 367-377. https://doi.org/10.1016/j.jalz.2010.07.004
@article{498507b54c244b17be9aa136d4c3aeaf,
title = "Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials",
author = "L.S. Schneider and R.E. Kennedy and G.R. Cutter and N.C. Fox",
year = "2010",
doi = "10.1016/j.jalz.2010.07.004",
language = "Undefined/Unknown",
volume = "6",
pages = "367--377",
journal = "Alzheimers & Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "5",
}
Schneider, LS, Kennedy, RE, Cutter, GR & Fox, NC 2010, 'Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials' Alzheimers & Dementia, vol. 6, no. 5, pp. 367-377. https://doi.org/10.1016/j.jalz.2010.07.004
Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. / Schneider, L.S.; Kennedy, R.E.; Cutter, G.R.; Fox, N.C.
In: Alzheimers & Dementia, Vol. 6, No. 5, 2010, p. 367-377.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials
AU - Schneider, L.S.
AU - Kennedy, R.E.
AU - Cutter, G.R.
AU - Fox, N.C.
PY - 2010
Y1 - 2010
U2 - 10.1016/j.jalz.2010.07.004
DO - 10.1016/j.jalz.2010.07.004
M3 - Article
VL - 6
SP - 367
EP - 377
JO - Alzheimers & Dementia
JF - Alzheimers & Dementia
SN - 1552-5260
IS - 5
ER -
Schneider LS, Kennedy RE, Cutter GR, Fox NC. Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers & Dementia. 2010;6(5):367-377. https://doi.org/10.1016/j.jalz.2010.07.004